Latest News Sep 21, 2023 Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy Download Share Facebook Twitter LinkedIn Email View all Press Releases Upcoming Events More events are coming soon. View all Events Stock Quote Price Change Volume Oct 4, 2023 8:36 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.